Global Review of Plasma Collection State for Preparation of Plasma-Drived Medicines

Document Type : Review Article

Authors

1 PhD in Medical Biotechnology, Assistant Professor, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

2 MD. Specialist in Community Medicine, Professor, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

3 PhD. Pathologist, Professor, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

4 PhD. Pathologist, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

10.48305/jims.v43.i819.0676

Abstract

Background: Human plasma is an essential source of therapeutic proteins, and plasmapheresis is the primary method of its collection. This study examines the status of plasma collection in Iran and other countries, analyzing the impact of management and incentive policies on the self-sufficiency and health of donors and patients. The World Health Organization and international blood transfusion organizations emphasize voluntary plasma donation, as it reduces the risk of infectious disease transmission, ensures donor safety, and promotes equitable access to blood products.
Article description: In Iran, plasmapheresis is conducted exclusively by private centers, offering monetary compensation above minimum wages. The Iranian Blood Transfusion Organization (IBTO) participates in the preparation of plasma-derived medicines only through surplus recovered plasma. Considering the IBTO’s achievement of 100% voluntary blood donation, its active involvement in plasma collection could attract voluntary donors, reduce the frequency of donations per individual, minimize complications from frequent donations, and improve donor health. In European countries, plasmapheresis is either conducted solely by public centers voluntarily (e.g., Australia, France) or with the involvement of private sectors and primarily using monetary incentives (e.g., Germany, Netherlands). Locating private plasmapheresis centers in low-income areas reflects policies aimed at attracting donors through monetary incentives, which jeopardize donor health and increase reliance on vulnerable populations.
Conclusion: Enhancing public awareness about the benefits of voluntary plasma donation, public sector involvement, updating apheresis equipment, regular monitoring of donor health, providing non-monetary incentives, and utilizing advanced pathogen pathogen reduction technologies represent effective steps toward achieving self-sufficiency and and providing safe plasma-derived medicines.

Highlights

منصوره شهبازی دستجرده: Google Scholar, PubMed

مهتاب مقصودلو: Google Scholar, PubMed

صدیقه امینی کافی آباد: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Rivera, J, Lozano M. Plasmapheresis and plasma donation: Challenges in the blood/plasma supply Chain. Plasmatology, 2022. 16: p. 26348535221107565.
  2. Plasma Fractionation Market: Global Forecast to [2028 August 28, 2024]; Available from: https://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html.
  3. New plasma donation approaches in Europe. August 28, 2024 n.d. [cited 2024 August 28, 2024]; Available from: https://www.euneedsmoreplasma.com/images/plasma-donation/chap6.pdf.
  4. Blood safety and availability. [2023 August 28, 2024]; Available from: https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability.
  5. Lacetera N, Macis M, Slonim R. Economic rewards to motivate blood donations. Science 2013; 340(6135): 927-8.
  6. Slonim, R., C. Wang, and E. Garbarino. The market for blood. Journal of Economic Perspectives 2014; 28(2): 177-96.
  7. Hoad VC, Castrén J, Norda R, Pink J. A donor safety evidence literature review of the short‐and long‐term effects of plasmapheresis. Vox Sang 2024; 119(2): 94-101.
  8. Burkhardt T, Rothe R, Moog R. Immunoglobulin G levels during collection of large volume plasma for fractionation. Transfus Apher Sci 2017; 56(3): 417-20.
  9. Tchulzki T, Seidel K, Storch H, Karges H,Kiessig S, Schneider S, et al. A prospective multicentre study on the safety of long‐term intensive plasmapheresis in donors (SIPLA). Vox Sang 2006; 91(2): 162-73.
  10. Ciszewski TS, Ralston S, Acteson D, Wasi S, Strong SJ. Protein levels and plasmapheresis intensity. Transfus Med 1993; 3(1): 59-65.
  11. Friedman BA, Schork MA, Mocniak JL, Oberman HA. Short‐term and long‐term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion 1975; 15(5): 467-72.
  12. van den Hurk K, Schroyens N, Mikkelsen S, Severijns P, De Buck E, et al. Balancing donor health and plasma collection: a systematic review of the impact of plasmapheresis frequency. Transfusion Medicine Reviews 2024; 38(4): 150851.
  13. Dehshal MH. Paid plasma in low-and middle-income countries: The strategy or the strategy-frustrating: A short account of Iran experience involved. Global Journal of Transfusion Medicine 2020; 5(2): 232.
  14. Ochoa A, Shaefer HL, Grogan-Kaylor A. The interlinkage between blood plasma donation and poverty in the United States. The Journal of Sociology & Social Welfare 2021; 48: 56.
  15. Pourfathollah AA, Shamsasenjan K, Dehshal MH. Paid plasma versus voluntary nonremunerated plasma collection for plasma-derived medicine: Iran experience with a short glance at a few countries. Glob J Transfus 2023; 8(1): 10-16.
  16. Frey BS, Oberholzer-Gee F. The cost of price incentives: An empirical analysis of motivation crowding-out. Am Econ Rev 1997; 87(4): 746-55.
  17. Masser BM, White KM, Hyde MK, Terry DJ. The psychology of blood donation: current research and future directions. Transfus Med Rev 2008; 22(3): 215-33.
  18. Mellström C. Johannesson M. Crowding out in blood donation: was Titmuss right? J Eur Econ Assoc 2008; 6(4): 845-63.
  19. Ryan RM, Deci EL. Intrinsic and extrinsic motivations: Classic definitions and new directions. Contemp Educ Psychol 2000; 25(1): 54-67.
  20. Titmuss RM, McGregor M. The gift relationship: from human blood to social policy. Can Med Assoc J 1999; 160(1): 91.
  21. Use, C.f.M.P.f.H. Guideline on plasma-derived medicinal products. European Medicines Agency, Londres. Relatório de Estágio Profissionalizante–Hospital de Proximidade de Lamego. [21 July 2011]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf.
  22. The Sixty-third World Health Assembly. Availability, Safety and Quality of Blood Products. 2010 [cited 63 August 28, 2024]; Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf.
  23. World Health Organization. Utilization and supply of human blood and blood products. World Health Assembly Resolution. [28 May 1975]. Available from: https://www.who.int/publications/i/item/utilization-and-supply-of-human-blood-and-blood-products-(wha28.72)
  24. World Health Organization. Towards 100% voluntary blood donation: a global framework for action. [1 January 2010]. Available from: https://www.who.int/publications/i/item/9789241599696
  25. COUNCIL OE. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Oviedo: COE; 1997.
  26. WHO Expert Group. Expert Consensus Statement on achieving self‐sufficiency in safe blood and blood products, based on voluntary non‐remunerated blood donation (VNRBD). Vox Sang 2012; 103(4): 337-42.
  27. Farrugia A, Penrod J, Bult JM. Payment, compensation and replacement–the ethics and motivation of blood and plasma donation. Vox Sang 2010; 99(3): 202-11.
  28. Toumi, M., D. Urbinati, and E.-E. Commission, An EU-Wide Overview of the Market of Blood, Blood Components Plasma Derivatives Focusing on Their Availability for Patients. [8 April 2015]. Available from: https://health.ec.europa.eu/publications/eu-wide-overview-market-blood-blood-components-and-plasma-derivative-focusing-their-availability_en
  29. Koch E, Leiße A, Veseli B, Jensen J, Spekman M, EM, et al. Incentives for plasma donation. Vox Sang 2024; 119(8): 775-84.
  30. Kluszczynski T, Rohr S, Ernst R. Key economic and value considerations for plasma-derived medicinal products (PDMPs) in Europe. White paper commissioned by the Plasma Protein Therapeutics Association (PPTA); 2020.
  31. Pant S, Bagha R, McGill S. International plasma collection practices: project report. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021.
  32. Plasma Donation in Canada. 2018. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/activities/fact-sheets/plasma-donation-canada.html
  33. McLaughlin, K. Blood for money: my journey in the industry buying poor Americans’ plasma. Available from: https://www.theguardian.com/us-news/2023/mar/23/selling-blood-plasma-donations-us-health.
  34. Amini‐Kafiabad S, Pourfatollah AA. Viral safety of recovered plasma for contract fractionation; an Iranian experience, 2006–2015. Transfus Med 2022; 32(1): 64-70.
  35. Sanaei M-J, Abolghasemi H. Plasma industry in Iran: Challenges and opportunities. Iranian Journal of Blood and Cancer 2023; 15(2): 97-112.
  36. Graf C, Oteng-Attakora K, Ferguson E, Vassallo R, Merz EM. Biomedical excellence for safer transfusion collaborative. blood donor incentives across 63 countries: The BEST Collaborative Study. Transfus Med Rev 2023; 38(2): 150809.
  37. Association, P.P.T. Plasma donation: new thinking to serve Europe’s patients. 2021; Available from: https://www.euneedsmoreplasma.com/images/plasma-donation/updated%20dec%202022/plasma_core_policy_report_2022web.pdf
  38. Thorpe R, Masser BM, Nguyen L, Gemelli CN, Davison TE. Bringing new plasma donors back: testing the efficacy of telephone and e‐mail communications with first‐time donors. Transfusion 2020; 60(7): 1463-9.
  39. Hajinasrollah G, Maghsudlu M, Nazemi AM, Teimourpour A, Tabatabai M, Sedaghat A, et al. The effect of motivational strategy on voluntary plasma donation, a field trial. Transfus Apher Sci 2023; 62(1): 103518.
  40. Association, P.P.T., key facts on the private sector’s contribution to plasma collection in the eu. Plasma Protein Therapeutics Association 2023. Available from: https://cdn.prod.website-files.com/642ed7d22ef52d80053b0822/67dac37614d03a4292123b8d_KEY%20FACTS%20ON%20THE%20PRIVATE%20SECTORS%20CONTRIBUTION%20TO%20PLASMA%20COLLECTION%20IN%20THE%20EU.pdf
  41. Developing A Donor Management System. Available from: https://fastercapital.com/topics/developing-a-donor-management-system.html.
  42. Rossi, F., et al. How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems? Vox Sang 2011; 101(2): 176-7.
  43. Maghsudlu M, Nasizadeh S, Abolghasemi H, Ahmadyar S. Blood donation and donor recruitment in Iran from 1998 through 2007: ten years' experience. Transfusion 2009; 49(11): 2346-51.
  44. Hashemi S, Maghsudlu M, Nasizadeh S, Esmaielifar G, Pourfathollah AA. Effective ways to retain first‐time blood donors: a field‐trial study. Transfusion 2019; 59(9): 2893-8.

Abolghasemi H, Maghsudlu M, Amini Kafi-Abad S, Cheraghali A. Introduction to Iranian Blood Transfusion Organization and Blood Safety in Iran. Iran J Public Health 2009; 38(Supple 1): 82-7.

Journal of Isfahan Medical School
Volume 43, Issue 819
3rd Week, August
July and August 2025
Pages 676-694

Files

History

  • Receive Date: 07 January 2025
  • Accept Date: 25 January 2025

Share

How to cite

Statistics